Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

329 ARTÍCULOS , VIENDO DEL 256 AL 270

Non-pharmacological interventions and neuroplasticity in early stage Alzheimer's disease

Herholz SC, Herholz RS, Herholz K.

Expert Rev Neurother. 2013 Nov;13(11):1235-45. doi: 10.1586/14737175.2013.845086. Epub 2013 Oct 17.

Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease

Alagiakrishnan K, Sankaralingam S, Ghosh M, Mereu L, Senior P.

Discov Med. 2013 Dec;16(90):277-86.

New treatment strategies for Alzheimer's disease: is there a hope?

Aprahamian I, Stella F, Forlenza OV.

Indian J Med Res. 2013 Oct;138(4):449-60.

At the end of a very hard day, people find some reason to believe

Robert P.

J Alzheimers Dis. 2013;34(1):295-6. doi: 10.3233/JAD-121637.

Targeted recruitment using cerebrospinal fluid biomarkers: implications for Alzheimer's disease therapeutic trials

Barnes J, Bartlett JW, Fox NC, Schott JM.

J Alzheimers Dis. 2013;34(2):431-7. doi: 10.3233/JAD-121936.

State of the science: use of biomarkers and imaging in diagnosis and management of Alzheimer disease

Fraller DB.

J Neurosci Nurs. 2013 Apr;45(2):63-70. doi: 10.1097/JNN.0b013e3182829024.

Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer´s disease-like phenotype of a commonly used mouse model

Cuadrado-Tejedor M, Ricobaraza AL, Torrijo R, Franco R, Garcia-Osta A.

Curr Pharm Des. 2013;19(28):5076-84. doi: 10.2174/1381612811319280006.

Alzheimer's disease drug development: translational neuroscience strategies

Cummings JL, Banks SJ, Gary RK, Kinney JW, Lombardo JM, Walsh RR, Zhong K.

CNS Spectr. 2013 Jun;18(3):128-38. doi: 10.1017/S1092852913000023. Epub 2013 Mar 11.

Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease

Leclerc B, Abulrob A.

ScientificWorldJournal. 2013;2013:589308. doi: 10.1155/2013/589308. Epub 2013 Feb 5.

Clinical trials in predementia stages of Alzheimer disease

Pillai JA, Cummings JL.

Med Clin North Am. 2013 May;97(3):439-57. doi: 10.1016/j.mcna.2013.01.002. Epub 2013 Feb 22.

Alzheimer's disease treated patients showed different patterns for oxidative stress and inflammation markers

Gubandru M, Margina D, Tsitsimpikou C, Goutzourelas N, Tsarouhas K, Ilie M, Tsatsakis AM, Kouretas D.

Food Chem Toxicol. 2013 Nov;61:209-14. doi: 10.1016/j.fct.2013.07.013. Epub 2013 Jul 16.

A phase 3 trial of semagacestat for treatment of Alzheimer's disease

Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS; Alzheimer's Disease Cooperative Study Steering Committee; Siemers E, Sethuraman G, Mohs R; Semagacestat Study Group.

N Engl J Med. 2013 Jul 25;369(4):341-50. doi: 10.1056/NEJMoa1210951.

Clinical pharmacology of novel anti-Alzheimer disease modifying medications

Caraci F, Bosco P, Leggio GM, Malaguarnera M, Drago F, Bucolo C, Salomone S.

Curr Top Med Chem. 2013;13(15):1853-63. doi: 10.2174/15680266113139990141.

Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization

Zotova E, Bharambe V, Cheaveau M, Morgan W, Holmes C, Harris S, Neal JW, Love S, Nicoll JA, Boche D.

Brain. 2013 Sep;136(Pt 9):2677-96. doi: 10.1093/brain/awt210. Epub 2013 Aug 13.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias